Cargando…
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells
Despite new agent development and short-term benefits in patients with colorectal cancer (CRC), metastatic CRC cure rates have not improved due to high rates of 5-fluorouracil (5-FU)/leucovorin/oxaliplatin (FOLFOX)-resistance and a clinical therapeutic plateau. At the same time, this treatment regim...
Autores principales: | Narayan, Satya, Ramisetti, Srinivasa, Jaiswal, Aruna S., Law, Brian K., Singh-Pillay, Ashona, Singh, Parvesh, Amin, Shantu, Sharma, Arun K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115410/ https://www.ncbi.nlm.nih.gov/pubmed/30384048 http://dx.doi.org/10.1016/j.ejmech.2018.10.052 |
Ejemplares similares
-
Triarylethylene-indolin-2,3-dione molecular conjugates: design, synthesis, docking studies and anti-proliferation evaluation
por: Kumar, Sumit, et al.
Publicado: (2019) -
Diastereoselective approach to rationally design tetrahydro-β-carboline–isatin conjugates as potential SERMs against breast cancer
por: Sharma, Bharvi, et al.
Publicado: (2019) -
1H-1,2,3-Triazole Tethered
Nitroimidazole–Isatin Conjugates: Synthesis, Docking, and Anti-Proliferative
Evaluation against Breast Cancer
por: Kumar, Sumit, et al.
Publicado: (2018) -
NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations
por: Narayan, Satya, et al.
Publicado: (2017) -
Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)